Using Molecular Symmetry to Form New Drugs: Hydroxymethyl-Substituted 3,9-Diazatetraasteranes as the First Class of Symmetric MDR Modulators

More is not always better: Until now it was considered that modulators of P-glycoprotein-associated multidrug resistance in cancer treatment showed greater inhibitory activity with an increasing number of moieties that could participate in hydrogen bonds. This theory has been questioned for the first time with a new class of symmetrical inhibitors 1 based on hydroxymethyl-3,9-diazatetraasteranes.